Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week Low - What's Next?

Key Points

• Kailera Therapeutics (NASDAQ: KLRA) hit a new 52-week low, trading as low as $18.39 after closing at $19.30 the prior day.
• Despite the slide, Wall Street sentiment is still mostly positive: analysts have issued multiple Buy/Outperform/Overweight ratings, with an average target price of $42.75.
• Insiders have been buying aggressively, including large purchases by directors Andrew T. Kaplan and Adam Koppel; insiders bought 10.46 million shares worth about $167.4 million over the last 90 days.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report)'s share price hit a new 52-week low during trading on Thursday . The company traded as low as $18.39 and last traded at $18.41, with a volume of 45587 shares traded. The stock had previously closed at $19.30.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on KLRA. TD Cowen started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a "buy" rating and a $57.00 target price on the stock. Zacks Research raised Kailera Therapeutics to a "hold" rating in a research note on Wednesday, May 13th. Wall Street Zen cut Kailera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 30th. Evercore assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an "outperform" rating on the stock. Finally, JPMorgan Chase & Co. started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an "overweight" rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $42.75.

Kailera Therapeutics Price Performance

The business's fifty day moving average price is $21.01. The company has a market capitalization of $2.36 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share for the quarter.

Insider Transactions at Kailera Therapeutics

In other Kailera Therapeutics news, Director Andrew T. Kaplan acquired 8,398,438 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the purchase, the director owned 26,255,581 shares in the company, valued at approximately $420,089,296. The trade was a 47.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Adam Koppel bought 1,562,500 shares of the company's stock in a transaction on Monday, April 20th. The shares were acquired at an average price of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the acquisition, the director directly owned 22,583,268 shares in the company, valued at $361,332,288. This represents a 7.43% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 10,460,938 shares of company stock valued at $167,375,008 in the last 90 days.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.